Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
- 1 July 1995
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 346 (8970), 265-269
- https://doi.org/10.1016/s0140-6736(95)92163-x
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancerEuropean Journal Of Cancer, 1993
- Systematic overview (metaanalysis) of all randomized trials of treatment of prostate cancerCancer, 1993
- Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancerCancer, 1993
- Combination treatment in M1 prostate cancerCancer, 1993
- Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized TrialJournal of Urology, 1993
- Orchidectomy versus Zoladex® plus Eulexin® in patients with metastatic prostate cancer (EORTC 30853)The Journal of Steroid Biochemistry and Molecular Biology, 1990
- A Controlled Trial of Castration With and Without Nilutamide in Metastatic Prostatic CarcinomaCancer, 1990
- A Phase III Trial of Zoladex and Flutamide Versus Orchiectomy in the Treatment of Patients With Advanced Carcinoma of the ProstateCancer, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensThe Prostate, 1983